A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei.

Published in: The Journal of infectious diseases (2024)

The MFA is expected to expedite Pvs25-based TBV development without dependence on blood from P. vivax-infected patients in endemic areas for evaluation.

Keyphrases

randomized controlled trial
systematic review
high throughput
plasmodium falciparum
single cell